The 36-month beta value for ALLO is also noteworthy at 0.81. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 4 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALLO is 142.43M, and at present, short sellers hold a 26.01% of that float. The average trading volume of ALLO on November 26, 2024 was 2.09M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ALLO) stock’s latest price update
The stock price of Allogene Therapeutics Inc (NASDAQ: ALLO) has jumped by 3.17 compared to previous close of 2.21. Despite this, the company has seen a gain of 6.05% in its stock price over the last five trading days. zacks.com reported 2024-11-25 that Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
ALLO’s Market Performance
ALLO’s stock has risen by 6.05% in the past week, with a monthly drop of -6.56% and a quarterly drop of -14.93%. The volatility ratio for the week is 6.30% while the volatility levels for the last 30 days are 9.00% for Allogene Therapeutics Inc The simple moving average for the last 20 days is -13.13% for ALLO’s stock, with a simple moving average of -26.43% for the last 200 days.
Analysts’ Opinion of ALLO
Many brokerage firms have already submitted their reports for ALLO stocks, with Oppenheimer repeating the rating for ALLO by listing it as a “Outperform.” The predicted price for ALLO in the upcoming period, according to Oppenheimer is $11 based on the research report published on August 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $11. The rating they have provided for ALLO stocks is “Overweight” according to the report published on May 31st, 2024.
ALLO Trading at -14.83% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.52% of loss for the given period.
Volatility was left at 9.00%, however, over the last 30 days, the volatility rate increased by 6.30%, as shares sank -14.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.39% lower at present.
During the last 5 trading sessions, ALLO rose by +6.05%, which changed the moving average for the period of 200-days by -47.95% in comparison to the 20-day moving average, which settled at $2.62. In addition, Allogene Therapeutics Inc saw -28.97% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Parker Geoffrey M., who proposed sale 36,404 shares at the price of $2.84 back on Oct 21 ’24. After this action, Parker Geoffrey M. now owns shares of Allogene Therapeutics Inc, valued at $103,501 using the latest closing price.
Douglas Earl Martin, the Officer of Allogene Therapeutics Inc, proposed sale 28,310 shares at $2.79 during a trade that took place back on Aug 21 ’24, which means that Douglas Earl Martin is holding shares at $78,844 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -6501.95 for the present operating margin
- -1437.6 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -6591.37. The total capital return value is set at -0.5. Equity return is now at value -54.15, with -43.56 for asset returns.
Currently, EBITDA for the company is -300.29 million with net debt to EBITDA at -0.13. When we switch over and look at the enterprise to sales, we see a ratio of 11905.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.35.
Conclusion
In summary, Allogene Therapeutics Inc (ALLO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
